06.05.2025
Dr. Klaus Schwamborn Joins Advisory Board of EBViously GmbH
EBViously GmbH is pleased to announce that Dr. Klaus Schwamborn, Head of Vaccine Development at the German Center for Infection Research (DZIF), has joined the company’s advisory board as DZIF
representative.
International Patent for Novel EBV Vaccine and Antibody Platform
EBViously GmbH is pleased to announce the publication of the international patent application WO2025209940, titled “EBV Vaccine and Antibodies" . The patent covers innovative antigen designs and antibody candidates aimed at EBV-associated disease for a novel and promissing vaccine antigen.
24.02.2026
19.03.2025
World Vaccine Congress 2025
Dr. Sebastian Goy (CEO) will present our new exciting data for EBV-001 at the World Vaccine Congress in Washington in April 2025
12.03.2025
Interview for German news website
Prof. Hammerschmidt was interviewed by a German news website on EBV and Infectious Mononucleosis following the case of a German professional soccer player who was sidelined due to a diagnosis of IM.